Humalog ILPS (insulin lispro protamine suspension) / Eli Lilly - LARVOL DELTA

Lilly reports full Q4 2024 financial results and provides 2025 guidance (PRNewswire) - "For Q4 2024, worldwide Mounjaro revenue increased 60% to $3.53 billion. U.S. revenue was $2.63 billion, an increase of 25%, reflecting continued strong demand and increased supply...Revenue outside the U.S. increased to $898.9 million compared with $100.5 million in Q4 2023...For Q4 2024, worldwide Trulicity revenue decreased 25% to $1.25 billion. U.S. revenue decreased 36% to $799.8 million...Revenue outside the U.S. increased 9% to $450.4 million...For Q4 2024, U.S. Zepbound revenue was $1.91 billion, compared with $175.8 million in Q4 2023...For Q4 2024, worldwide Humalog revenue increased 69% to $619.9 million. U.S. revenue was $405.8 million compared with $167.6 million in Q4 2023, driven by higher realized prices primarily due to a one-time impact in Q4 2023 related to the implementation of list price decreases. Revenue outside the U.S. was $214.1 million, an increase of 8%, driven by higher realized prices in China and, to a lesser extent, increased volume."

Commercial • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus